



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Olsen et al.

Docket No.: PF363C2

Application No.: 10/771,418

Confirmation No.: 4060

Filed: February 5, 2004

Art Unit: 1644

For: Fc Receptors and Polypeptides

Examiner: M. A. Belyavskiy

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Agent for Applicants hereby directs the Examiner's attention to references AA-BJ listed on the attached form PTO/SB/08.

Copies of references AA-BI were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/907,421, filed July 16, 2001, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/907,421 for copies of references AA-BI. A copy of reference BJ is submitted herewith.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Date: _____

8/16/2004


Respectfully submitted,



Doyle A. Siever (Reg. No. 47,088)
Agent for Applicants

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850
(301) 354-3932 (phone)

MJP/DAS/PF



Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/771,418
				Filing Date	February 5, 2004
				First Named Inventor	Olsen et al.
				Group Art Unit	1644
				Examiner Name	Michail A. Belyavskyi
Sheet	1	of	5	Attorney Docket Number	PF363C2

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,198,342		Maliszewski	03/30/1993	
	AB	5,328,987		Maliszewski	07/12/1994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AC		WO 98/09638		Brigham and Women's Hospital	03/12/1998		
	AD		WO 98/24906		Schering Corporation	06/11/1998		


OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AE	KATZ, et al., "Mouse mast cell gp49B1 contains two immunoreceptor...", Proc. Natl. Acad. Sci. USA, 93:10809-10814 (1996)			
	AF	HIBBS, et al., "Molecular cloning of a human immunoglobulin G Fc receptor", Proc. Natl. Acad. Sci. USA, 85-2240-2244 (1988)			
	AG	RAGHAVAN, et al., "Fc Receptors and their Interactions with Immunoglobulins", Annu. Rev. Cell Dev. Biol., 12:181-220 (1996)			
	AH	STENGELIN, et al., "Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning", EMBO J., 7(4):1053-1059 (1988)			
	AI	SAMARIDIS, et al., "Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and...", Eur. J. Immunol., 27(3):660-665 (1997)			

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/771,418
				Filing Date	February 5, 2004
				First Named Inventor	Olsen et al.
				Group Art Unit	1644
				Examiner Name	Michail A. Belyavskyi
Sheet	2	of	5	Attorney Docket Number	PF363C2

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AJ	COLONNA M., Genbank Accession No. AF014923 (12/05/1995)	
	AK	BORGES, L., Genbank Accession No. AF025527 (12/02/1997)	
	AL	ARM J.P., Genbank Accession No. U91926 (09/12/1997)	
	AM	VINOGRADOVA, T.V., Genbank Accession No. T41304 (01/23/1995)	
	AN	ZHAO, EST Accession No. AQ532231 (1997)	
	AO	NAGASE T., GEN EMBL Accession NO. AB002362 (1997)	
	AP	ENSERINK M., "Patent Office May Raise The Bar on Gene Claims", Science, 287:1196-1197 (02/18/2000)	
	AQ	PERESS, N.S., et al., "Monoclonal antibodies identify three IgG Fc receptors in normal human central nervous system", Clin. Immunol. Immunopathol. 53(2 Pt 1):268-280 (1989)	
	AR	PERESS, N. S., et al., "High avidity periventricular IgG-Fc receptor activity in human and rabbit brain", Clin. Immunol. Immunopathol. 42(2):229-238 (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
		Application Number		10/771,418	
		Filing Date		February 5, 2004	
		First Named Inventor		Olsen et al.	
		Group Art Unit		1644	
		Examiner Name		Michail A. Belyavskyi	
Sheet		3		of 5	
		Attorney Docket Number		PF363C2	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	AS	WOODROOFE, M.N., <i>et al.</i> , "Fc receptor density, MHC antigen expression and superoxide production are increased in interferon-gamma-treated microglia isolated from adult rat brain", <i>Immunology</i> , 68(3):421-426 (1989)	
	AT	ZHANG, G., <i>et al.</i> "Identification of a Novel Class of Mammalian Fcγ Receptor, J. Immunol. 155:1534-1541 (1995)	
	AU	WILSON, et al. "Assessing Annotation Transfer to Genomics: Quantifying the relations between protein sequence, structure, and function through traditional and probabilistic scores," <i>J. Mol. Biol.</i> 17:233-249 (2000).	
	AV	DUNWELL, et al., "Microbial Relatives of Seed Storage Proteins of Higher Plants: Conservation of Structure and Diversification of Function during Evolution of the Cupin Superfamily," <i>Microbiol. Mol. Biol. Rev.</i> , 64:153-179 (2000).	
	AW	WEBSTER'S NINTH NEW COLLEGIATE DICTIONARY, Merriam Webster Inc., Page 568 (1985)	

Examiner Signature	Date Considered
--------------------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	4	of	5	Application Number	10/771,418
				Filing Date	February 5, 2004
				First Named Inventor	Olsen et al.
				Group Art Unit	1644
				Examiner Name	Michail A. Belyavskyi
				Attorney Docket Number	PF363C2

U.S. PATENT DOCUMENTS						
Examiner Initials ⁶	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ⁶	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ⁶	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	AX	ATTWOOD, "The Babel of Bioinformatics", Science, 290:471-473 (2000)	
	AY	SIGMA CHEMICAL COMPANY, "Biochemicals Organic Compounds for Research and Diagnostic Reagents", Catalogue, pgs. 1422-1423 (1994)	
	AZ	GERHOLD et al., "It's the genes! EST access to human genome content", Bioessays, 18:973-981 (1996)	
	BA	WELLS et al., "The chemokine information source: identification and characterization of novel chemokines...", J. Leukocyte Biology, 61:545-550 (1997)	
	BB	RUSSELL et al., "Structural Features can be Unconserved in Proteins with Similar Folds", J. Molec. Biology, 244:332-350 (1994)	
	BC	SKOLNICK et al., Trends in Biotech., 18(1):34:39, 2000	
	BD	VAN REGENMORTEL, Methods: A Companion to Methods of Enzymology 9:465-472, 1996	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/771,418
				Filing Date	February 5, 2004
				First Named Inventor	Olsen et al.
				Group Art Unit	1644
				Examiner Name	Michail A. Belyavskyi
Sheet	5	of	5	Attorney Docket Number	PF363C2

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ² (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1 ⁶
	BE	COLMAN et al., Research in Immunology 145(1):33-36, 1994	
	BF	ABAZA et al., Journal of Protein Chemistry 11(5):433-444, 1992	
	BG	LEDERMAN et al., Molecular Immunology 28:1171-1181, 1991	
	BH	LI et al., PNAS 77:3211-3214, 1980	
	BI	NGO et al., Protein Folding problem and Tertiary Structure prediction, 1994, Merz et al., (ed), Birkhauser, Boston, MA, pp.433 and 492-495	
	BJ	TEDLA et al., "Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7", PNAS, 100(3):1174-1179 (2003)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.